Syngene International, a global contract research, development, and manufacturing organization (CRDMO), is expanding its commercial biologics facility [Unit 3] in Bengaluru with a new GMP bioconjugation suite. This addition will enable Syngene to provide fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery to GMP manufacturing – positioning it among a select group of CDMOs with comprehensive ADC capabilities.
The OEB-5 rated suite is designed to accelerate ADC development by combining Monoclonal Antibody (mAb) production and GMP bioconjugation at a single site, complementing Syngene’s existing expertise in payload and linker manufacturing. Expected to be operational within this financial year, the facility will also support advanced conjugates and related modalities. Collocated analytical and bioanalytical capabilities will ensure seamless integration across the entire development lifecycle.
“The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays,” said Alex Del Priore, Head - LM CDMO, Syngene International. “By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing.” He added.
Building on a decade of experience in ADC discovery and deep expertise in handling high-potency payloads, linkers, and mAbs within GMP-compliant facilities, Syngene is expanding its capabilities to support clinical programs, with plans to scale up to commercial production in the future.
The upgraded laboratories will provide process development, analytical characterization, and scale-up support for both early- and late-stage programs. This expansion strengthens Syngene’s position as an agile, science-driven partner for biotech and biopharma clients advancing ADC programs. It also underscores the company’s commitment to innovation and operational excellence in ADCs, a rapidly growing segment with a robust pipeline of molecules entering clinical development.